FLU WARS: Egg-free Flublok, quad vax backed for 2013-14 arsenal
This article was originally published in Scrip
As the US heads into 2013-14 influenza season this fall, among the new vaccines health care providers will have for the first time in their arsenal of weapons to fight the virus will be Protein Sciences' trivalent recombinant hemagglutinin vaccine Flublok, which won the backing of a panel of advisers to the US Centers for Disease Control and Prevention (CDC) on 20 June as the product of choice for adults allergic to eggs.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.